Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression

Purpose: Clear cell renal cell carcinoma (ccRCC) has recently been redefined as a highly heterogeneous disease. In addition to genetic heterogeneity, the tumor displays risk variability for developing metastatic disease, therefore underscoring the urgent need for tissue-based prognostic strategies applicable to the clinical setting. We have recently employed the novel PET/magnetic resonance (MR) image modality to enrich our understanding of how tumor heterogeneity can relate to gene expression and tumor biology to assist in defining individualized treatment plans. Experimental Design: ccRCC patients underwent PET/MR imaging, and these images subsequently used to identify areas of varied intensity for sampling. Samples from 8 patients were subjected to histologic, immunohistochemical, and microarray analysis. Results: Tumor subsamples displayed a range of heterogeneity for common features of hypoxia-inducible factor expression and microvessel density, as well as for features closely linked to metabolic processes, such as GLUT1 and FBP1. In addition, gene signatures linked with disease risk (ccA and ccB) also demonstrated variable heterogeneity, with most tumors displaying a dominant panel of features across the sampled regions. Intriguingly, the ccA- and ccB-classified samples corresponded with metabolic features and functional imaging levels. These correlations further linked a variety of metabolic pathways (i.e., the pentose phosphate and mTOR pathways) with the more aggressive, and glucose avid ccB subtype. Conclusions: Higher tumor dependency on exogenous glucose accompanies the development of features associated with the poor risk ccB subgroup. Linking these panels of features may provide the opportunity to create functional maps to enable enhanced visualization of the heterogeneous biologic processes of an individual's disease. Clin Cancer Res; 22(12); 2950–9. ©2016 AACR.

[1]  R. Motzer,et al.  Targeted therapy for metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[3]  M. Remzi,et al.  Rationale for percutaneous biopsy and histologic characterisation of renal tumours. , 2012, European urology.

[4]  K. Junker,et al.  A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. , 2011, The Journal of urology.

[5]  M. Kattan,et al.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. , 2014, European urology.

[6]  Ciprian Catana,et al.  PET/MRI for Neurologic Applications , 2012, The Journal of Nuclear Medicine.

[7]  A. Drzezga,et al.  First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses , 2012, The Journal of Nuclear Medicine.

[8]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[9]  M. Reiser,et al.  The role of functional imaging in the era of targeted therapy of renal cell carcinoma , 2014, World Journal of Urology.

[10]  Gyan Bhanot,et al.  Abstract 1996: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns , 2010 .

[11]  R. Uzzo,et al.  Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. , 2011, Hematology/oncology clinics of North America.

[12]  Robert G. Uzzo,et al.  Heterogeneity and renal mass biopsy: a review of its role and reliability , 2014, Cancer biology & medicine.

[13]  E. Wallen,et al.  Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. , 2012, European urology.

[14]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[15]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[16]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[17]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[18]  R. Motzer,et al.  The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling , 2014, Cancer medicine.

[19]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[20]  The Cancer Genome Atlas Research Network COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[21]  Zoltan Szallasi,et al.  Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers , 2014, European urology.

[22]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[24]  A. Hamid,et al.  Targeted Therapy for Metastatic Renal Cell Carcinoma. , 2017, Acta medica Indonesiana.

[25]  Rosamonde E Banks,et al.  Renal cancer biomarkers: the promise of personalized care , 2012, BMC Medicine.

[26]  H. Axelson,et al.  Kidney cancer. , 2013, Seminars in cancer biology.

[27]  C. Brinckerhoff,et al.  Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinoma , 2005, Oncogene.

[28]  L. Gunaratnam,et al.  Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. , 2005, Cancer research.

[29]  Brian Keith,et al.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. , 2008, Cancer cell.

[30]  S. Yasuda,et al.  Significance of 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT‐1) expression in the cancer , 2002, International journal of urology : official journal of the Japanese Urological Association.

[31]  Lawrence A. Donehower,et al.  The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.

[32]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[33]  W. Rathmell,et al.  Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib , 2012, Nuclear medicine communications.

[34]  S. Clifford,et al.  Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL‐independent pathway in clear cell renal tumourigenesis , 1998 .

[35]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[36]  D. Appelbaum,et al.  FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer , 2013, Cancer medicine.

[37]  J. Ochocki,et al.  Fructose-1, 6-bisphosphatase opposes renal carcinoma progression , 2014, Nature.

[38]  M. Uder,et al.  Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  U. Tateishi,et al.  Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report , 2010, BMC Cancer.